Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinwei versus Gleevec as first-line treatment for newly diagnosed chronic-phase chronic myeloid leukemia
ChiCTR-ONC-14004845Phase 4Completed
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: 6-month complete cytogenetic response rate. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR-ONC-14004845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-14004845.